The Science Behind Our Technology
Why sEVs Excel Over ctDNA
Small extracellular vesicles (sEVs), also known as exosomes (30-150 nm in diameter), are membrane-bound nanoparticles released by cells. They facilitate intercellular communication by transferring bioactive cargo (proteins, lipids, RNAs) to recipient cells and offer a fundamentally different window for detecting metastatic progression. Rather than detecting genetic material from dying cells, this approach captures dynamic phenotypic changes from live, actively metastasising cancer cells through epithelial-mesenchymal transition (EMT) protein signatures. EMT is a key driver of metastasis, allowing tumor cells to detach from the primary site, invade surrounding tissues, and disseminate to distant organs.
1
Early Detection
Captures EMT phenotypic changes months before genomic signals appear, enabling intervention during the subclinical window when treatment is most effective.
2
Superior Stability
Abundant, stable biomarkers (10⁹-10¹² particles/mL) protected by double-membrane structure, providing reliable detection with minimal degradation throughout processing.
3
Unique Edge: Longitudinal Phenotypic Tracking
Biopsomic's sEV tests aim to establish patient-specific baselines from living cell protein signals, independently of tumor burden. This enables dynamic tracking of EMT for evolving, personalized metastatic risk profiles – empowering proactive therapy guidance in a multi-omics era.
About Us
Biopsomic AG is a Swiss MedTech company advancing a new frontier in early cancer risk detection by decoding the proteomic signatures carried by small extracellular vesicles (sEVs). Our breakthrough platform (process-development stage) harnesses ultra-sensitive technology to pinpoint the aggressive signals from mesenchymal cells in solid tumors, spotting biological shifts and metastatic risks months before traditional liquid biopsy methods. This unlocks the golden window when cancer is still localized and treatable - empowering curative surgery (with or without adjuvant therapy) to achieve 70–90% five-year survival rates. We are not just detecting cancer; we are transforming outcomes, one life-saving insight at a time. Join us in closing the gap.
The Oncology Challenge
Cancer metastasis is a biologically complex process that remains a major challenge in the oncology clinic. Today, approximately 90 % of the 10 million annual cancer deaths are driven by metastatic spread rather than the primary tumour. The progression of malignant tumors leads to the development of secondary tumors in various organs, including bones, the brain, liver, and lungs. This metastatic process severely impacts the prognosis of patients, significantly affecting their quality of life and survival rates. To change outcomes, oncology needs a reliable, scalable test that can detect cancer cells earlier and predict metastatic risk at diagnosis – enabling personalised treatment that saves lives and reduces healthcare costs.
The Missed Window
Conventional liquid biopsies detect cancer only once tumour cells begin to die, sEVs expose the silent window months before that, capturing protein signals from active, viable cells that stay measurable across the entire disease course.
Clinical applications of ctDNA assays for patients with cancer and expected DNA levels in different phases of the disease:
Figure: * Normalized expected plasma signal intensity: ctDNA tumor fraction/copies (curve adopted from J. Pascal et al.: ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group; https://www.annalsofoncology.org/article/S0923-7534(22)01721-5/fulltext)
Clinically Verified Performance
Published a proof-of-concept study; "An EMT induced extracellular vesicle prognostic signature in non-small cell lung cancer (NSCLC)", (Nature, Communications Biology, 2023).
Verified in 100 NSCLC patients (stage I-IIIA) with exceptional performance: AUC 0.96, 86% sensitivity, and 96% specificity, Hazard Ratio 14.6.
Stratification: 4-protein signature (Biopsomic 4-Plex) → Early vs Late progression
Median DFS:
- Early progression (high-risk): ≈ 8 months
- Late progression (low-risk): ≈ 66 months
High-risk patients start with a high EMT-sEV signal and tend to stay biologically high risk, even when tumor mass is small or temporarily controlled.
Get In Touch
Grow with us…
Interested in learning more?
We welcome enquiries about our technology, investment opportunities, clinical collaborations, and partnership possibilities. Our team is ready to discuss how Biopsomic's innovative sEV proteomics platform can transform early cancer detection and improve patient outcomes.
© 2025 Biopsomic AG | All rights reserved | New Frontiers Diagnostics